--- schema_version: "secwatch.filing_event.v1" accession: "0000950170-23-023257" form_type: "8-K" ticker: "ATYR" cik: "0001339970" company_name: "aTYR PHARMA INC" filed_at: "2023-05-19T23:59:59+00:00" generated_at: "2026-06-14T19:35:45.609721+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.5 calibrated_materiality_score: 0.5 confidence: "high" source: SEC EDGAR --- # aTyr Pharma stockholders approve doubling of authorized shares and equity plan increase ## Summary - Authorized common shares increased from 85M to 170M via Charter Amendment filed May 18, 2023. - 2015 Stock Plan share reserve increased by 4M shares to 7,711,868 (post-reverse split). - Two Class II directors elected: Timothy P. Coughlin and Jane A. Gross, Ph.D., until 2026. - Ernst & Young ratified as independent auditor for FY 2023 with 44.5M votes for. - Advisory say-on-pay compensation approved with 37.2M for, 1.0M against. ## SEC filing metadata - accession: 0000950170-23-023257 - form_type: 8-K - ticker: ATYR - cik: 0001339970 - company_name: aTYR PHARMA INC - filed_at: 2023-05-19T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.5 - calibrated_materiality_score: 0.5 - confidence: high - sec_items: 5.02, 5.07, 5.03, 5.05, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017023023257/0000950170-23-023257-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017023023257/life-20230517.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000950170-23-023257 - JSON: https://secwatch.observer/filing/0000950170-23-023257.json - Plain text: https://secwatch.observer/filing/0000950170-23-023257.txt ## Key facts - Governance Changes aTYR PHARMA INC: Increased authorized shares of common stock from 85,000,000 to 170,000,000 via Certificate of Amendment to Restated Certificate of Incorporation (effective 2023-05-18). - Change: charter amendment - Effective: 2023-05-18 source text: On May 18, 2023, following stockholder approval of the Authorized Share Proposal at the Annual Meeting, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Restated Certificate of Incorporation (the “Charter Amendment”) to increase the authorized number of shares of common stock from 85,000,000 to 170,000,000. evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017023023257/0000950170-23-023257-index.htm - Governance Changes aTYR PHARMA INC: Board approved and adopted amendments to the Code of Business Conduct and Ethics to augment compliance protections and clarity (effective 2023-05-17). - Change: code of ethics - Effective: 2023-05-17 source text: On May 17, 2023, the Board adopted and approved certain amendments to the Company’s Code of Business Conduct and Ethics, as reflected in an amended version of the Code of Business Conduct and Ethics (the “Code”). evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017023023257/0000950170-23-023257-index.htm - Shareholder Votes aTYR PHARMA INC shareholders approved Election of two Class II directors. - Proposal: director election - Outcome: passed source text: Proposal 1 – Election of Class II Directors. Director Nominee Votes For Withhold Broker Non-Vote Timothy P. Coughlin 34,867,452 3,431,326 6,317,414 Jane A. Gross, Ph.D. 34,876,816 3,421,962 6,317,414 evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017023023257/0000950170-23-023257-index.htm - Shareholder Votes aTYR PHARMA INC shareholders approved Ratification of the appointment of Ernst and Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023 at the 2023-12-31 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-12-31 source text: Proposal 2 – Ratification of the appointment of Ernst and Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. Votes For Votes Against Abstain Broker Non-Vote 44,505,484 99,431 11,277 — evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017023023257/0000950170-23-023257-index.htm - Shareholder Votes aTYR PHARMA INC shareholders approved Approval of the Authorized Share Proposal to increase the authorized number of shares of common stock from 85,000,000 to 170,000,000. - Proposal: charter amendment - Outcome: passed source text: Proposal 5 – Approval of the Authorized Share Proposal to increase the authorized number of shares of common stock from 85,000,000 to 170,000,000. Votes For Votes Against Abstain Broker Non-Vote 41,984,002 518,951 2,113,239 — evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017023023257/0000950170-23-023257-index.htm - Shareholder Votes aTYR PHARMA INC shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. - Proposal: say on pay - Outcome: passed source text: Proposal 3 – Approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. Votes For Votes Against Abstain Broker Non-Vote 37,246,069 1,007,212 45,497 6,317,414 evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017023023257/0000950170-23-023257-index.htm - Shareholder Votes aTYR PHARMA INC shareholders approved Approval of an amendment to the 2015 Stock Plan. - Proposal: equity plan - Outcome: passed source text: Proposal 4 – Approval of an amendment to the 2015 Stock Plan. Votes For Votes Against Abstain Broker Non-Vote 30,235,893 8,020,783 42,102 6,317,414 evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017023023257/0000950170-23-023257-index.htm - Shareholder Votes aTYR PHARMA INC shareholders approved Approval of authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 4 or 5. - Outcome: passed source text: Proposal 6 – Approval of authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 4 or 5. Votes For Votes Against Abstain Broker Non-Vote 36,384,724 8,179,700 51,768 — evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017023023257/0000950170-23-023257-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.